Form 4: AVITA Medical Director Receives Equity Awards Following Shareholder Approval

AVITA Medical, Inc. Director Cary Guy Vance was granted 10,022 Restricted Stock Units and 4,295 stock options, with these equity awards receiving stockholder approval on June 4, 2025.

Summary

• Cary Guy Vance, a Director of AVITA Medical, Inc. (RCEL), was granted equity awards on January 21, 2025.
• The awards include 10,022 Restricted Stock Units (RSUs), each representing a contingent right to one share of Common Stock.
• These RSUs are subject to time-based vesting criteria and will vest 12 months following the grant date of January 21, 2025.
• Additionally, Mr. Vance received 4,295 stock options, each allowing the purchase of one share of Common Stock.
• The stock options have an exercise price of $8.73, which was the closing price of AVITA Medical's common stock on Nasdaq on the grant date.
• These options become exercisable on January 21, 2026, and expire on January 21, 2035.
• Both the RSU and stock option grants were subject to and received approval from the Company's stockholders on June 4, 2025.
• Following these transactions, Mr. Vance beneficially owns 35,771 shares of Common Stock (including unvested RSUs) and 4,295 stock options.

Sentiment

Score: 7

Explanation: The document reflects a positive aspect of corporate governance by aligning director interests with shareholders through equity awards, which were also approved by stockholders. It is a routine compensation disclosure and does not indicate any negative operational or financial news.

Positives

• The granting of equity awards to a director helps align their interests with those of the shareholders, promoting long-term value creation.
• The awards were subject to and received stockholder approval, indicating good corporate governance practices.

Future Outlook

This filing pertains to director compensation and does not provide forward-looking statements or guidance regarding the company's operational or financial performance.

Management Comments

• The Board of Directors approved the grant of 4,295 options to acquire 4,295 shares of Common Stock to each of its non-executive directors on January 6, 2025, with a grant date of January 21, 2025, and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $8.73.
• This option grant was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025.

Industry Context

The granting of equity awards such as Restricted Stock Units and stock options is a common practice for compensating non-executive directors in publicly traded companies across various industries. This method is widely used to align the interests of directors with those of shareholders and to incentivize long-term performance.

Comparison to Industry Standards

• The structure of these equity awards, including time-based vesting for RSUs and a fixed exercise price for options based on the grant date's closing price, is consistent with standard compensation practices for non-executive directors in the biotechnology and medical device sectors.
• The requirement for stockholder approval for such grants is a common corporate governance benchmark, ensuring transparency and accountability in executive and director compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity awards align the director's financial interests with shareholder value, potentially leading to more favorable long-term strategic decisions and improved company performance.

Next Steps

• The Restricted Stock Units (RSUs) granted on January 21, 2025, are expected to vest on January 21, 2026, subject to time-based vesting criteria.
• The stock options granted on January 21, 2025, will become exercisable on January 21, 2026.

Key Dates

Keywords

AVITA Medical, RCEL, SEC Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, Stock Options, Equity Awards, Corporate Governance